Furthermore, in vivo delivery of EphA2 siRNA using nanoliposomal in ovarian cancer has demonstrated effective targeting of cancer cell and remarkable anticancer effects [167, 168]. This evidence concerns the gene EPHA2 and ovarian carcinoma.